• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经皮电渗给药维拉帕米和地塞米松与阴茎硬结病内注射的比较。

Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease.

机构信息

Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Andrology. 2013 Jan;1(1):129-32. doi: 10.1111/j.2047-2927.2012.00018.x. Epub 2012 Oct 23.

DOI:10.1111/j.2047-2927.2012.00018.x
PMID:23258641
Abstract

To compare the efficacy of transdermal electromotive administration and intra-lesional injection of verapamil plus dexamethasone for the treatment of Peyronie's disease. Patients with Peyronie's disease of less than 2-year duration were randomized into two groups of transdermal electromotive administration and intra-lesional injection of verapamil plus dexamethasone. During the 6-week therapy period, a single weekly dose of 10 mg verapamil and 4 mg dexamethasone solution was administered to 30 patients in each group either by transdermal electromotive method or via the conventional injection method by a syringe connected to a 25 G needle. Evaluations of plaque length, width, and volume, penile curvature, erectile dysfunction and penile deviations were carried out before and after 1 and 3 months of the interventions. Erectile pain was reduced in the electromotive group from a mean of 5.1-1.0 in scale of 10 and from 5.4 to 3.6 in the injection group (p = 0.006). Regarding plaque length, plaque width, penile curvature plaque volume and erectile dysfunction, the electromotive administration group showed better results which, however, were not statistically significant. (p > 0.05). Transdermal electromotive drug administration yielded comparable results as against current conventional intra-lesional injection technique and fared better in controlling erectile pain.

摘要

比较经皮电渗动和病灶内注射维拉帕米加地塞米松治疗 Peyronie 病的疗效。将病程少于 2 年的 Peyronie 病患者随机分为两组,分别接受经皮电渗动和病灶内注射维拉帕米加地塞米松治疗。在 6 周的治疗期间,每组 30 例患者每周接受一次 10mg 维拉帕米和 4mg 地塞米松溶液,通过经皮电渗动法或通过连接到 25G 针头的注射器进行常规注射。在干预前、1 个月和 3 个月后,对斑块长度、宽度和体积、阴茎弯曲、勃起功能障碍和阴茎偏斜进行评估。电动组的勃起疼痛从平均 10 分的 5.1 分降至 1.0 分,注射组从 5.4 分降至 3.6 分(p=0.006)。在斑块长度、斑块宽度、阴茎弯曲、斑块体积和勃起功能障碍方面,电渗动给药组的结果更好,但无统计学意义(p>0.05)。经皮电渗动药物给药与目前的常规病灶内注射技术相比具有相当的效果,在控制勃起疼痛方面表现更好。

相似文献

1
Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie's disease.经皮电渗给药维拉帕米和地塞米松与阴茎硬结病内注射的比较。
Andrology. 2013 Jan;1(1):129-32. doi: 10.1111/j.2047-2927.2012.00018.x. Epub 2012 Oct 23.
2
A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease.一项使用维拉帕米和地塞米松经皮电动给药治疗佩罗尼氏病的前瞻性随机研究。
J Urol. 2004 Apr;171(4):1605-8. doi: 10.1097/01.ju.0000116450.82816.2c.
3
Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial.维拉帕米与生理盐水用于佩罗尼氏病的电动力药物给药:一项双盲、安慰剂对照试验。
J Urol. 2007 Mar;177(3):972-5. doi: 10.1016/j.juro.2006.10.065.
4
Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease.维拉帕米和地塞米松经皮电动给药治疗佩罗尼氏病。
BJU Int. 2003 Jun;91(9):825-9. doi: 10.1046/j.1464-410x.2003.04242.x.
5
Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results.经皮电动多药物给药治疗佩罗尼氏病:初步结果。
J Androl. 2000 Jan-Feb;21(1):85-90.
6
The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie's disease.维拉帕米和地塞米松经皮电动给药治疗佩罗尼氏病的有效性。
Int Urol Nephrol. 2009;41(1):113-8. doi: 10.1007/s11255-008-9408-x. Epub 2008 Jul 1.
7
Transdermal iontophoresis with verapamil and dexamethasone in the acute phase of peyronie's disease. Our experience.在佩罗尼氏病急性期使用维拉帕米和地塞米松进行经皮离子导入疗法。我们的经验。
Arch Esp Urol. 2012 Oct;65(8):745-51.
8
[Transdermal iontophoresis with dexamethasone and verapamil for Peyronie's disease].[地塞米松和维拉帕米经皮离子导入治疗佩罗尼氏病]
Actas Urol Esp. 2005 Nov-Dec;29(10):955-60. doi: 10.1016/s0210-4806(05)73376-3.
9
Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study.病灶内注射维拉帕米溶解佩罗尼氏病斑块的应用:一项长期单盲研究。
Urology. 1998 Apr;51(4):620-6. doi: 10.1016/s0090-4295(97)00700-0.
10
Intralesional injection of the calcium channel blocker Verapamil in Peyronie's disease: A critical review.阴茎硬结症中钙通道阻滞剂维拉帕米的腔内注射:一项关键性综述。
Arch Ital Urol Androl. 2020 Oct 2;92(3). doi: 10.4081/aiua.2020.3.253.

引用本文的文献

1
Transdermal Drug Delivery Systems: Methods for Enhancing Skin Permeability and Their Evaluation.经皮给药系统:增强皮肤渗透性的方法及其评价
Pharmaceutics. 2025 Jul 20;17(7):936. doi: 10.3390/pharmaceutics17070936.
2
Acute Phase Peyronie's Disease: Where Do We Stand?佩罗尼氏病急性期:我们目前的状况如何?
Cureus. 2024 Aug 17;16(8):e67054. doi: 10.7759/cureus.67054. eCollection 2024 Aug.
3
Non-surgical therapies for Peyronie's disease.非手术治疗 Peyronie 病。
Cochrane Database Syst Rev. 2023 Jul 17;7(7):CD012206. doi: 10.1002/14651858.CD012206.pub2.
4
The Immunological Microenvironment and the Emerging Role of Stem Cells Therapy in Peyronie's Disease: A Systematic Narrative Review.免疫微环境与干细胞疗法在 Peyronie 病中的新作用:系统叙事性综述。
Int J Mol Sci. 2023 Jan 1;24(1):777. doi: 10.3390/ijms24010777.
5
A systematic review of non-surgical management in Peyronie's disease.阴茎硬结症非手术治疗的系统评价。
Int J Impot Res. 2023 Sep;35(6):523-532. doi: 10.1038/s41443-022-00633-w. Epub 2022 Oct 26.
6
Molecular Mechanisms and Current Pharmacotherapy of Peyronie's Disease: A Review.佩罗尼氏病的分子机制与当前药物治疗:综述
Front Pharmacol. 2021 May 20;12:643641. doi: 10.3389/fphar.2021.643641. eCollection 2021.
7
Recent advances in managing Peyronie's disease.佩罗尼氏病治疗的最新进展。
F1000Res. 2020 May 20;9. doi: 10.12688/f1000research.20557.1. eCollection 2020.
8
Minimally invasive therapies for Peyronie's disease: the current state of the art.佩罗尼氏病的微创治疗:当前的技术水平
Transl Androl Urol. 2020 Mar;9(Suppl 2):S269-S283. doi: 10.21037/tau.2019.08.06.
9
Laser Therapy for Peyronie's Disease: A Randomized Control Double-Blind Pilot Study.佩罗尼氏病的激光治疗:一项随机对照双盲试验性研究。
J Lasers Med Sci. 2019 Fall;10(Suppl 1):S37-S42. doi: 10.15171/jlms.2019.S7. Epub 2019 Dec 1.
10
--- Recent advances in managing Peyronie's disease.佩罗尼氏病治疗的最新进展
F1000Res. 2016 Sep 26;5. doi: 10.12688/f1000research.9041.1. eCollection 2016.